ArborGen Holdings Limited logo

Disclosure of Senior Managers Relevant Interest

Insider/Shareholder Notice11 December 2022ARBIndustrials

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and

Name of listed issuer:

ArborGen Holdings Limited

Date this disclosure made:

11 December 2022

Date of last disclosure:

3 August 2022

Director or senior manager giving disclosure

Full name(s):

Andrew Mark Baum

Name of listed issuer:

ArborGen Holdings Limited

Name of related body corporate (if applicable):

N/A

Position held in listed issuer:

Chief Executive Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:

ARB Ordinary Shares

Nature of the affected relevant interest(s):

Right to acquire restricted share units (RSUs)

convertible into ARB Ordinary Shares, subject to

performance targets and vesting criteria being met

For that relevant interest-

Number held in class before acquisition or disposal:

2021 RSUs (awarded): 486,080

Ordinary Shares: 1,188,507

Number held in class after acquisition or disposal:

2021 RSUs (awarded): 486,080

Ordinary Shares: 1,188,507

Current registered holder(s):

Andrew Mark Baum

Registered holder(s) once transfers are registered:

Andrew Mark Baum

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:

N/A

Class of underlying financial products:

N/A

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying

financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative(if any):

The price specified in the terms of the derivative (if any):

Any other details needed to understand how the amount of the consideration

payable under the derivative or the value of the derivative is affected by the value

of the underlying financial products:

For that derivative,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the

relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates: 1

Details of transactions requiring disclosure-
Date of transaction:3 December 2022

Nature of transaction: Pursuant to an Agreement entered into on 3 December

2022 between Andrew Baum, ArborGen Holdings

Limited (ARB) and ArborGen Inc (the Agreement), all

outstanding Restricted Share Units (RSUs) held by

Andrew Baum and all outstanding cash awards

pursuant to the 2021 LTI plan shall be terminated,

effective as of the date when Andrew Baum's

successor as the Chief Executive Officer of each of

ArborGen Inc. and ARB is appointed (the Relevant

Date). The relevant interest that Andrew Baum has in

486,080 RSUs changed from the date of entry into the

Agreement because under the Agreement his

entitlement to those RSUs will cease from the Relevant

Date.

Notwithstanding the foregoing, under the Agreement if

Andrew Baum is an active employee of the Company

on July 7, 2023, Andrew Baum shall be entitled to

receive 486,080 ordinary shares in ARB and $13,938

in cash in connection with the vesting of the final one

third of an LTI Plan award under the 2021 LTI Plan,

and the 2020 Conditional RSU Agreement.

The Agreement also provides Andrew Baum with an

entitlement to receive a number of ordinary shares in

ARB equivalent to US$405,736.00 on the Relevant

Date issued at the Average Market Price at the

relevant time.

Name of any other party or parties to the transaction (if known):N/A

The consideration, expressed in New Zealand dollars, paid or received for the

acquisition or disposal. If the consideration was not in cash and cannot be readily

by converted into a cash value, describe the consideration:

No cash consideration is payable in respect of the

RSUs. See above in relation to the entitlement to

certain ordinary shares in the Company.

Number of financial products to which the transaction related: 486,080 RSUs

If the issuer has a financial products trading policy that prohibits directors or

senior managers from trading during any period without written clearance (a

closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:No

Whether prior written clearance was provided to allow the acquisition or disposal to

proceed during the closed period:

N/A

Date of the prior written clearance (if any):

N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:N/A

Nature of relevant interest:N/A

For that relevant interest,-

Number held in class:N/A

Current registered holder(s):N/A

For a derivative relevant interest,-

Type of derivative:N/A

Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying

financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration

payable under the derivative or the value of the derivative is affected by the value

of the underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the

relevant interest in the derivative:

Certification

I, certify that, to the best of my knowledge and belief, the information contained in

this disclosure is correct and that I am duly authorised to make this disclosure by

all persons for whom it is made.

Signature of director or officer:

Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

11 December 2022

Name and title of authorised person:

Sharon Ludher-Chandra Company Secretary

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.

  • AGL — Accordant Group Limited: Ongoing disclosure notice.
    2022-11-29

    Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: Accordant Group Limited Date this disclosure made: 29-Nov-22 Date of last disclosu…”

  • AGL — Accordant Group Limited: Ongoing disclosure notice.
    2022-11-20

    Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: Accordant Group Limited Date this disclosure made: 21-Nov-22 Date of last disclosu…”

  • TAH — Third Age Health Services Limited: D&O Ongoing Disclosure Notice
    2022-12-21

    Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: Third Age Health Services Limited Date this disclosure made: 21 December 2022 Date…”